The prophylaxis and treatment with antiviral agents of respiratory syncytial virus infections

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 4, 2012, Pages 139-150

  Najarro, Pilar ^a   Angell, Richard ^b   Powell, Kenneth ^c  

^a Biolty SL   (Spain)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c Q Chip Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; 1 MORPHOLINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2 [[2 [[1 (2 AMINOETHYL) 4 PIPERIDINYL]AMINO] 4 METHYL 1H BENZIMIDAZOL 1 YL]METHYL] 6 METHYL 3 PYRIDINOL; ACETAMIDE; ALN 01; ANTIVIRUS AGENT; ASPARTATE CARBAMOYLTRANSFERASE; BENZAZEPINE DERIVATIVE; BENZIMIDAZOLE; BENZODIAZEPINE DERIVATIVE; BTA 9881; CARBAMOYL PHOSPHATE SYNTHASE; CIGLITAZONE; GUANINE NUCLEOTIDE BINDING PROTEIN; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPYLENE GLYCOL; PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RIBAVIRIN; ROSIGLITAZONE; RSV 604; SMALL INTERFERING RNA; TARIBAVIRIN; TMC 353121; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 14637; YM 53403; YM53403;

BRONCHIOLITIS; CELL FUSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HUMAN; IC 50; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; LUNG TRANSPLANTATION; MEMBRANE PERMEABILITY; MORBIDITY; MORTALITY; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; ORTHOMYXOVIRUS; PARAMYXOVIRUS; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROVIRUS; REVIEW; RNA INTERFERENCE; VACCINATION; VIRUS LOAD; VIRUS REPLICATION; BIOLOGICAL MODEL; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; MEDICAL RESEARCH; METHODOLOGY;

ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 84860624662     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1873     Document Type: Review

References (77)

1. Storey S. Respiratory syncytial virus market. Nat Rev Drug Discov 2010; 9:15-16.
2. Welliver RC. Pharmacotherapy of respiratory syncytial virus infection. Curr Opin Pharmacol 2010; 10:289-293.
3. Hall CB, Geiman JM, Biggar R, Kotok DI, Hogan PM, Douglas GR, Jr. Respiratory syncytial virus infections within families. N Engl J Med 1976; 294:414-419.
4. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 2003; 22 Suppl 2: S13-S18.
5. Johnson KM, Bloom HH, Mufson MA, Chanock RM. Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease. N Engl J Med 1962; 267:68-72.
6. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102 Suppl 1:27-30.
7. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003; 22 Suppl 2:S21-S32.
8. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.J Pediatr 2003; 143 Suppl 5:S127-S132.
9. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543-546.
10. Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002; 110:e20.
11. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncy-tial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-1555.
12. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010; 23:74-98.
13. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-421.
14. Groothuis JR, Simoes EA. Immunoprophylaxis and immunotherapy: role in the prevention and treatment of repiratory syncytial virus. Int J Antimicrob Agents 1993; 2:97-103.
15. Wright PF, Karron RA, Belshe RB, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25:7372-7378.
16. Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease patho-genesis and early attempts at prevention. Adv Ther 2011; 28:91-109.
17. Habibi MS, Patel S, Openshaw P. Hot topics in the prevention of respiratory syncytial virus disease. Expert Rev Vaccines 2011; 10:291-293.
18. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immu-noprophylaxis. Adv Ther 2011; 28:110-125.
19. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329:1524-1530.
20. Weisman LE. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J 2003; 22 Suppl 2: S33-S37.
21. Pollack P, Groothuis JR, Development and use of palivi-zumab (Synagis): a passive immunoprophylactic agent for R S V. J infect Chemother 2002; 8: 201-206.
22. Scott LJ, Lamb HM. Palivizumab. Drugs 1999; 58:305-311.
23. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531-537.
24. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syn-cytial virus in young children with hemodynamically signif-cant congenital heart disease. J Pediatr 2003; 143:532-540.
25. Stewart DL. Studies recommending palivizumab restriction have serious defciencies. J Manag Care Pharm 2010; 16:509-511.
26. Mejías A, Chavez-Bueno S, Rios AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49:4700-4707.
27. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavi-zumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:e35-e51.
28. Powell KL, Alber DG. Development of antivirals against respiratory syncytial virus. In P Cane (Editor). Respiratory syncytial virus. Perspectives in medical virology. Amsterdam: Elsevier BV Publishers 2006; pp. 279-298.
29. Yu KL, Sin N, Civiello RL, et al. Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailabil-ity. Bioorg Med Chem Lett 2007; 17:895-901.
30. Wang XA, Cianci CW, Yu KL, et al. Respiratory syncytial virus fusion inhibitors. Part 5: optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorg Med Chem Lett 2007; 17:4592-4598.
31. Sin N, Venables BL, Combrink KD, et al. Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorg Med Chem Lett 2009; 19:4857-4862.
32. Combrink KD, Gulgeze HB, Thuring JW, et al. Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorg Med Chem Lett 2007; 17:4784-4790.
33. Blade H, Carron EA, Jackson HM, et al., inventors. Astra-Zeneca UK Ltd., Arrow Therapeutics Ltd, assignee. Ben-zimidazole derivatives as RSV protein inhibitors and their preparation, pharmaceutical compositions and use in the treatment of respiratory syncytial virus infections. United States patent WO/2010/103306. 2010 September 16.
34. Bonfanti JM, Meyer C, Doublet C, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholino-propylaminobenzimidazole derivative (TMC353121). J Med Chem 2008; 51:875-896.
35. Roymans D, De Bondt HL, Arnoult E, et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A 2010; 107:308-313.
36. Rouan MC, Gevers T, Roymans D, et al. Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model. Antimicrob Agents Chem-other 2010; 54:4534-4539.
37. Lundin A, Bergstrom T, Bendrioua L, Kann N, Adamiak B, Trybala E. Two novel fusion inhibitors of human respiratory syncytial virus. Antiviral Res 2010; 88:317-324.
38. Douglas JL, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specifc interactions with F protein. J Virol 2003; 77:5054-5064.
39. Cook R. MDT-637, a novel antiviral treatment for respiratory syncytial virus infection. 7th International Respiratory Syncytial Virus (RSV) Symposium. 2-5 December 2010, Rotterdam, the Netherlands. Abstract 0.04
40. Quraishi OS, Stoddard CA, Black P, inventors; Conjuchem Biotechnologies Inc., assignee. Long lasting modifed antifu-sogenic peptide for preventing HIV infection. United States patent WO/2008/144J90. 2008 November 27.
41. Peeples ME, Kennedy M, Ray W, inventors; Nationwide Children's Hospital, Inc., assignee. Methods and compositions relating to viral fusion proteins. United States patent 20100261155. 2010 October 14.
42. Park M, Matsuura H, Lamb RA, et al. A fuorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform. Anal Biochem 2001; 409:195-201.
43. Cortese R, Pessi A, inventors. Cormus SRL, assignee. Inhibitors of viral fusion an uses thereof. Italy patent WO/2010/089129. 2010 August 12.
44. Prudom CE, Karlsson L, Miller S, Williams J, Crowe J, Jr. Wright D. Structure activity relationship of heptad repeat peptide truncates that prevent viral fusion. 60th Southeast Regional Meeting of the American Chemical Society. 12-15 November 2008, Nashville, TN, USA. Abstract 17.
45. Harrison RS, Shepherd NE, Hoang HN, et al. Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A 2010; 107:11686-11691.
46. Kimura K, Mori S, Tomita K, et al. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res 2000; 47:41-51.
47. Kimura K, Ishioka K, Hashimoto K, et al. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res 2004; 61:165-171.
48. Malykhina O, Yednak MA, Collins PL, Olivo PD, Peeples ME. A respiratory syncytial virus replicon that is noncyto-toxic and capable of long-term foreign gene expression. J Virol 2011; 85:4792-4801.
49. Carter MC, Alber DG, Baxter RC, et al. 1,4-Benzodiaz-epines as inhibitors of respiratory syncytial virus. J Med Chem 2006; 49:2311-2319.
50. Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimi-crob Agents Chemother 2007; 51:3346-3353.
51. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specifc to ciliated cells, and without obvious cytopathology. J Virol 2002; 76:5654-5666.
52. Marty FM, Chemaly RF, Liakopoulou E, Dent JC, Powell KL. Randomised, placebo-controlled study to evaluate the safety and effcacy of RSV604 in adults with Respiratory Syncytial Virus (RSV) infection following stem sell transplantation. IX International symposium on Respiratory Virus Infection. 3-6 March 2007, Hong Kong SAR, China.
53. Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 2009; 326:1279-1283.
54. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of vira-zole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177:705-706.
55. Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavi-rin in antiviral therapies. Antivir Chem Chemother 2001; 12:261-272.
56. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 2010; 107:8800-8805.
57. Lin CC, Philips L, Xu C, Yeh LT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004; 44:265-275.
58. Arnold R, König K. Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells. Virology 2006; 350:335-346.
59. Otake K, Omoto S, Yamamoto T, et al. HIV-1 Nef protein in the nucleus infuences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS 2004; 18:189-198.
60. Sudo K, Miyazaki Y, Kojima N, et al. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 2005; 65:125-131.
61. Mackman RL, Sperandio D, Yang H, inventors; Gilead Sciences Inc., Preparation of thienobenzazepine derivatives as RSV inhibitors and useful in the treatment of RSV infection. United States patent WO/2011/00J842. 2011 January 13.
62. Mason SW, Lawetz C, Gaudette Y, et al. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identifcation of an inhibitor. Nucleic Acids Res 2004; 32:4758-4767.
63. Liuzzi M, Mason SW, Cartier M, et al. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA poly-merase. J Virol 2005; 79:13105-13115.
64. Olivo PD, Buscher BA, Dyall J, et al., inventors; Apath LLC, assignee. 4-Aminoquinoline compounds for treating virus-related conditions. United States patent WO/2006/093J18. 2006 September 8.
65. Lai SH, Stein DA, Guerreo-Plata A et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther 2008; 16:1120-1128.
66. Bonavia A, Franti M, Pusateri Keaney E, et al. Organic synthesis toward small-molecule probes and drugs special feature: identifcation of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A 2011; 108:6739-6744.
67. Shim MS, Kwon YJ. Effcient and targeted delivery of siRNA in vivo. FEBS J 2010; 277:4814-4827.
68. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-55.
69. Alvarez R, Elbashir S, Borland T, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucle-ocapsid defnes a potent antiviral strategy. Antimicrob Agents Chemother 2009; 53:3952-3962.
70. Bannister R, Rodrigues D, Murray EJ, Laxton C, Westby M, Bright H. Use of a highly sensitive strand-specifc quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease. Virol J 2010; 7:250-261.
71. Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531-538.
72. Hemida MG, Ye X, Thair S, Yang D. Exploiting the therapeutic potential of microRNAs in viral diseases: expectations and limitations. Mol Diagn Ther 2010; 14:271-282.
73. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 2004; 63:191-196.
74. DeVincenzo J P, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010; 182:1305-1314.
75. Bermingham A, Henrickson K, Hayden F, Zambon M. VII International Symposium on Respiratory Viral Infections. Antivir Ther 2007; 12:671-693.
76. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:2755-2763.
77. DeVincenzo J P, El Saleeby CM, Bush AJ. Respiratory syncy-tial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005; 191:1861-1868.